ACM
HRMY icon

Ashford Capital Management’s Harmony Biosciences HRMY Stock Holding History

Ashford Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-434,148
Closed -$14.2M – 94
2023
Q3 		$14.2M Sell
434,148
-14,890
-3% -$517K 2.09% 21
2023
Q2 		$15.8M Buy
449,038
+3,620
+0.8% +$125K 2.21% 21
2023
Q1 		$14.5M Buy
445,418
+88,780
+25% +$4.04M 2.18% 19
2022
Q4 		$19.7M Sell
356,638
-134,130
-27% -$7.37M 3.05% 13
2022
Q3 		$21.7M Sell
490,768
-176,480
-26% -$8.61M 3.32% 8
2022
Q2 		$32.5M Buy
667,248
+7,375
+1% +$332K 4.62% 4
2022
Q1 		$32.1M Sell
659,873
-34,910
-5% -$1.42M 3.46% 8
2021
Q4 		$29.6M Buy
694,783
+64,310
+10% +$2.56M 2.95% 10
2021
Q3 		$24.2M Sell
630,473
-7,560
-1% -$243K 2.2% 16
2021
Q2 		$18M Sell
638,033
-8,640
-1% -$259K 1.62% 32
2021
Q1 		$21.4M Buy
646,673
+373,723
+137% +$13.1M 2% 23
2020
Q4 		$9.87M Buy
+272,950
New +$11M 0.95% 36

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Ashford Capital Management's HRMY Position: Q4 2023 in Review

Ashford Capital Management sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 434,148 shares — an estimated $14.2M sold.

Ashford Capital Management first reported a position in HRMY in Q4 2020 and held it in 12 quarters. The position peaked at $32.5M in Q2 2022. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

  • Ashford Capital Management reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
  • Ashford Capital Management sold 434,148 Harmony Biosciences shares in Q4 2023, an estimated $14.2M.
  • Ashford Capital Management first reported a position in Harmony Biosciences in Q4 2020 and held it in 12 quarters.
  • Ashford Capital Management's Harmony Biosciences position peaked at $32.5M in Q2 2022.
  • 221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Ashford Capital Management's 13F filing for Q4 2023, filed 15 Feb 2024.